lorazepam

lorazepam
Name	Lorazepam
Tradename	Ativan, Temesta, others
Drug class	Benzodiazepine
Legal status	Varies by country
Routes of administration	Oral; intravenous; intramuscular
Metabolism	Hepatic (conjugation)
Elimination half-life	10–20 hours (average)

lorazepam

Lorazepam is a benzodiazepine medication used for the short-term management of anxiety, status epilepticus, and insomnia, and for sedation during procedures. It was developed and introduced during the mid-20th century and has been widely prescribed across North America, Europe, and Asia, appearing on essential medicines lists in many health systems. Major regulatory agencies and clinical guidelines from institutions such as the Food and Drug Administration, World Health Organization, and national health services have detailed indications and restrictions for its use.

Medical uses

Lorazepam is indicated for acute anxiety episodes and generalized anxiety disorder when short-term therapy is appropriate, and for procedural sedation in contexts such as radiology suites and minor surgery. It is an established option for seizure control, particularly as a first-line agent for treating status epilepticus in emergency medicine and pediatric practice, used alongside protocols from organizations like the American Heart Association and the European Resuscitation Council. In oncology and palliative care settings, it is employed for anticipatory nausea and as adjunctive sedation referenced in guidance from bodies including the National Institutes of Health and National Institute for Health and Care Excellence.

Contraindications and precautions

Contraindications include known hypersensitivity to benzodiazepines and severe respiratory insufficiency, where agents and policies from the Centers for Disease Control and Prevention and regional drug regulators advise caution. Use is contraindicated in acute narrow-angle glaucoma and is generally avoided during pregnancy because of links to neonatal sedation and withdrawal discussed in reports from the American College of Obstetricians and Gynecologists and teratology research. Elderly patients and those with comorbid hepatic impairment require dose adjustment per recommendations from societies such as the American Geriatrics Society and national formularies.

Adverse effects

Common adverse effects encompass sedation, dizziness, cognitive impairment, and ataxia, which have been examined in clinical evaluations published by academic centers like Johns Hopkins Hospital and university medical centers. Prolonged use can lead to tolerance, dependence, and withdrawal syndromes that have prompted guidance from the Substance Abuse and Mental Health Services Administration and addiction medicine groups including members of the Royal College of Psychiatrists. Respiratory depression and paradoxical reactions such as agitation have been reported in case series from emergency departments affiliated with institutions like Mayo Clinic and Cleveland Clinic.

Interactions

Lorazepam has clinically significant interactions with other central nervous system depressants such as opioids, alcohol, and barbiturates; co-prescribing guidance has been issued by the Drug Enforcement Administration-linked task forces and public health agencies. Concomitant use with enzyme inhibitors or inducers discussed by pharmacology divisions at universities such as Harvard Medical School and UCLA Health can alter effects, and combination with antipsychotics or antidepressants used in practice at institutions like Massachusetts General Hospital may increase sedation. Policy statements from regulatory authorities like the European Medicines Agency address risk mitigation for polypharmacy in outpatient and inpatient settings.

Pharmacology

Lorazepam is a positive allosteric modulator of the γ-aminobutyric acid A receptor complex, enhancing inhibitory neurotransmission in the central nervous system; fundamental receptor pharmacology has been elaborated by researchers at institutes such as the Salk Institute and Karolinska Institute. Its mechanism contributes to anxiolytic, anticonvulsant, sedative-hypnotic, and muscle-relaxant effects reported in translational research from centers like National Institute of Mental Health laboratories. Structure–activity relationships and binding site studies have been advanced in collaboration with chemistry departments at universities including California Institute of Technology and University of Oxford.

Pharmacokinetics

After oral administration, lorazepam is well absorbed and undergoes glucuronidation in the liver to inactive metabolites, with elimination parameters described in clinical pharmacology texts used at medical schools such as Columbia University and Yale School of Medicine. It does not depend heavily on cytochrome P450 oxidation, which distinguishes it from other benzodiazepines discussed in comparative reviews from regulatory agencies like the Australian Therapeutic Goods Administration and the Swissmedic authority. Renal excretion of conjugates and variability in half-life across populations have been characterized in pharmacokinetic studies from academic centers including University of Toronto and Imperial College London.

History and society

Lorazepam was introduced in the 1960s amid a wave of benzodiazepine development that included contemporaries marketed by pharmaceutical companies such as Roche and Wyeth; its social impact has been analyzed in public health literature from organizations like the World Bank and national commissions on drug policy. Over decades, prescribing patterns and regulatory responses have evolved in the context of drug safety advisories from agencies such as the Food and Drug Administration and class-action litigation documented in legal records in jurisdictions including United States courts. The drug has been referenced in clinical guidelines from professional societies including the American Psychiatric Association and has influenced debates about long-term psychotropic use in policy forums hosted by institutions like the Brookings Institution.

Category:Benzodiazepines